Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Humana Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.92, while Humana Inc trades at $384.63 (market cap $44.77B). The key difference: Humana Inc pays a 0.95% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Humana Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| FEPI | HUM | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $409.42 |
52-Week Low | $37.98 | $163.67 |
Market Cap | — | $44.77B |
Enterprise Value | — | $52.12B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI, the REX FANG & Innovation Equity Premium Income ETF, trades at $41.88, showing minimal daily movement with a 0.02% gain. The technical outlook is bullish based on moving averages, though oscillators are neutral. The ETF employs a covered call strategy on a concentrated basket of AI and mega-cap tech stocks, generating a high yield through weekly dividends, with recent payouts around $0.20-$0.21 per share. Recent news highlights its transition to weekly distributions and investor interest due to its aggressive income approach.
FEPI offers a high-yield opportunity through its covered call strategy, appealing for income-focused investors, but faces risks from NAV erosion in downturns and limited upside potential. The concentrated portfolio of volatile tech names increases exposure to sector-specific swings, requiring careful risk assessment for long-term holdings.
Humana (HUM) trades at $386.11, up 0.17% today, with a neutral technical outlook and mixed fundamentals. The stock shows strong revenue growth reaching $129.66B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent Q2 2026 earnings beat expectations with EPS of $7.61 versus $7.27 expected, while management focuses on Medicare Advantage margin expansion and cost reductions.
Outlook remains cautiously optimistic with a consensus price target of $409.93 offering 6% upside potential. Key opportunities include Medicare Advantage growth and operational efficiency gains, while risks involve margin pressure, regulatory changes in healthcare, and competitive threats. Analyst sentiment leans neutral with 57% hold ratings amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
